Results 171 to 180 of about 30,003 (287)
Biosimilarsubstitution wirtschaftlich nicht effizient – Epoetin-alfa-Biosimilar sicher und bewährt [PDF]
, 2011 openalex +1 more source
Diabetes, Obesity and Metabolism, Volume 27, Issue S5, Page 36-44, July 2025.Abstract Background The rising cost of insulins are significantly impacting health care expenditure, thereby limiting access to treatment for more people affected by diabetes. Fear and misunderstanding of insulin therapy have worsened with the emergence of biosimilar insulins. Biosimilars are not the same as generic medications.
A. Abitbol, L. Chu
wiley +1 more source
Current status and considerations on biosimilar in China [PDF]
, 2012 Junzhi Wang
openalex +1 more source
An overview of insulin therapy for the non‐specialist
Diabetes, Obesity and Metabolism, Volume 27, Issue S5, Page 3-15, July 2025.Abstract Nearly all health professionals, whatever their practice or speciality, now have contact with a significant number of insulin‐using people with diabetes. People with type 1 diabetes are nearly universally managed on more complex insulin regimens, increasingly with complex support technology, and with some understanding of the concepts ...
Philip D. Home
wiley +1 more source
Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data
Drug Design, Development and Therapy, 2017 Juan Pedro López-Siguero,1 Roland Pfäffle,2 Philippe Chanson,3 Mieczyslaw Szalecki,4,5 Nadja Höbel,6 Markus Zabransky6 1Servicio de Endocrinología Pediátrica, Hospital Materno-Infantil, Hospital Regional Universitario de M&
López-Siguero JP +5 more
doaj
Understanding the market dynamics of biosimilars
, 2016 Biosimilars represent an attractive market opportunity in the pharmaceutical industry. In order to understand the underlying market dynamics and to identify the success factors of the biosimilars market, a PEST (political, economic, social, technological)
Dassow, J. (Jonas) +3 more
core